Articles Tagged With: ticagrelor
-
Earlier Coronary Artery Bypass Grafting After Ticagrelor Discontinuation Is Safe
In a trial that included acute coronary syndrome patients treated with ticagrelor, undergoing coronary bypass surgery within two to three days was noninferior to the guideline-recommended five to seven days regarding severe bleeding.
-
Ticagrelor, a New Antiplatelet Agent, Shows Promise in Secondary Prevention of Ischemic Stroke
Ticagrelor is an antiplatelet agent that works by reversibly binding to P2Y12 adenosine diphosphate receptors on platelets, similar to the mechanism of action of clopidogrel. However, it is a direct-acting drug, and not a pro-drug, and does not need to be enzymatically converted to be active, like clopidogrel.
-
Ticagrelor in the Elderly: More Potent Platelet Inhibition Not Always Better
In a study of 14,000 elderly patients with acute myocardial infarction, treatment with ticagrelor was associated with higher risks of bleeding and all-cause death vs. clopidogrel.
-
Preventing Recurrent Stroke or Death After Ischemic Stroke, TIAs
The combination of ticagrelor and aspirin compared to aspirin alone was superior in reducing the risk of stroke or death within 30 days of an acute ischemic stroke or transient ischemic attack.
-
Ticagrelor Added to Aspirin Reduces Long-Term Risk of Recurrent Stroke or Death After Ischemic Stroke or TIAs
The Acute Stroke or Transient Ischemic Attack Treated with Ticagrelor and ASA for Prevention of Stroke and Death (THALES) study was designed to test the hypothesis that 30-day treatment with ticagrelor and aspirin would be superior to aspirin alone in reducing the risk of subsequent stroke or death in patients who had a non-cardioembolic ischemic stroke or transient ischemic attack.
-
When and How to Stop Dual Antiplatelet Therapy After PCI
Among patients with high-risk percutaneous coronary intervention who had completed three months of dual antiplatelet therapy with ticagrelor, patients who were randomized to ticagrelor alone experienced similar ischemic outcomes and a lower risk of bleeding at one year compared with those maintained on ticagrelor and aspirin.
-
Ticagrelor vs. Aspirin for Secondary Stroke Prevention — About the Same!
Ticagrelor was not found to be superior to aspirin in reducing the rate of stroke, myocardial infarction, or death within 90 days, but there was a trend toward a reduced rate of ischemic stroke, that did not reach statistical significance.